Read if you want one stock you can retire on

[Bozzie]

This is an obituary if I've ever read one.
UGLY...7 lawsuits against the company listed here including fraud...What a mess.
Bruce you see anything here at all worth salvaging?


PRED. EDGAR.
https://www.sec.gov/Archives/edgar/...0form10Kjune2020.htm#ITEM_3_LEGAL_PROCEEDINGS

 

[MattyMatt]

Brad Robinson and fraud? No way!


F'n knew better when I saw him as the CEO, but I'm over it as I wrote this off as a loss a long time ago, unfortunately...

 

[okie77]

I knew the moment I saw that prick in a interview he was shady. Oh well cant hit every investment. PRTS certainly making up for
Preds downfall.

 

[brucefan]

I hear PRED hired 35 new people in the last 60 days Brad will be gone by Jan Stay tuned

[h=1]Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer[/h][h=2][/h][FONT=&quot]https://www.globenewswire.com/news-...or-Treatment-Of-Inoperable-Liver-Cancer.html#[FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT]Email [FONT=&quot][/FONT]Print Friendly [FONT=&quot][/FONT]Share
December 09, 2020 09:15 ET | Source: RAFARMA PHARMACEUTICALS INC


Nicosia, Cyprus, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTCRAFA) is pleased to announce that one of the acquisition companies of the previously-announced Biocogency merger, Bebig LLC ([url]http://en.bebig.ru[/URL]), received an updated Russian registration certificate for the production and sale of nanostructured microspheres based on yttrium-90, used in the treatment of both primary and metastatic liver lesions. This will start industrial production and sale of ready-made batches of microspheres to medical institutions for use in radiotherapy of primary and metastatic liver tumors. This technology is recognized as the most effective for treating inoperable patients with liver cancer. In total, three companies in the world own this microsphere production technology: MDS Nordion (Canada), Sirtex (Australia), and now Bebig LLC (Russia).

“We have done a great job together with the Russian Ministry of Health and the Medical Radiological Scientific Center to allow patients to get priority access to the most modern and effective treatment methods. We not only managed to realize industrial production in our country and become the third company in the world for the production of microspheres, but with a 3x cost reduction of the drug in comparison with a foreign analogue," said Kirill Mayorov, General Director of Bebig LLC.
In the Russian Federation, about 8 thousand new cases of primary liver cancer are registered annually. Of these, radical surgery is possible only in 20% of cases. For the last 20 years, the leading world clinics in the treatment of liver cancer and liver metastases have been actively using this method of radioembolization, based on the introduction of microspheres containing a radionuclide drug into the vessels feeding the tumor. This method stops tumor growth in 90% of patients and increases life expectancy by 4-5 times compared to other standard treatments.
Bebig notes that the launch of the mass production of microspheres will satisfy the needs of not only patients with primary liver lesions (hepatocellular carcinoma), but radioembolization is also used to treat metastatic liver diseases caused by other tumors, such as metastases from breast cancer, colorectal cancer, and neuroendocrine tumors that have spread to the liver. Microspheres with a radioactive isotope of yttrium-90 are used as palliative care when cancer cannot be completely cured, but tumor growth can be slowed down and symptoms of the disease can be alleviated--providing a better quality of life for the patient. Radioembolization is also used when patients are not suitable candidates for surgical interventions or liver transplantation. This method is also used in combination with other treatments, such as chemotherapy, to maximize the effect of killing cancer cells. According to preliminary estimates, the annual requirements of Russian clinics for microspheres containing yttrium-90 amount to about 1000 individual doses.
Information about the company
BEBIG LLC is the first Russian manufacturer of micro-sources for the treatment of cancer using low-dose brachytherapy. The method is based on the implantation of micro-sources of radioactive radiation based on iodine-125 around the tumor perimeter and is a low-traumatic treatment method. It has been widely used in Europe and America for over 30 years. In Russia, low-dose brachytherapy is included in the list of high-tech medical care available under the program of state guarantees for the provision of free medical care to Russian Federation citizens and is the most cost-effective for both patients and medical institutions.
Since 2008, the BEBIG company has been introducing innovative methods of treating oncological diseases in the Russian market. Bebig has helped create 29 brachytherapy rooms in Russia, Armenia and Kazakhstan, in which more than 8000 patients suffering from oncological diseases of various organs were treated.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029


[h=2]Related Articles[/h]
[h=5]More articles issued by RAFARMA PHARMACEUTICALS INC[/h][h=5]More articles related to:[/h][h=5]Press releases[/h]
[/FONT]

 

[MattyMatt]

Brad gone would be the best news ever, lol. This thing may move just on that news, wishful thinking, haha.

It would definitely be a step in the right direction to get off the grays...

 

[brucefan]

RAFA

Great article today on Ilya Shpurov from RAFA

The pharmaceutical business in Russia: the path of the entrepreneur Ilya Shpurov

An investment is an operation that, after careful analysis, assumes the preservation of fixed assets and a satisfactory return.

Benjamin Graham


Today, in the midst of the crisis caused by the pandemic, every entrepreneur asks many questions: are growth points possible in business? Are there any strategies for optimal investment in the face of falling demand in most markets? What markets or their segments can you develop now? what business strategy to choose?


We decided to get answers to the questions posed by analyzing the existing business strategies of Ilya Yuryevich Shpurov, an entrepreneur and investor operating in the field of pharmaceuticals and biotech. His uncharacteristic Russian scientific view of doing business and the international perspective of its development has had a significant impact on the evolution of projects in his portfolio. The business approach of an entrepreneur is not only to find, buy out and in the future build from scratch a company that is in production decline, but also to establish production, to develop it in crisis circumstances, thanks to the skillful crisis management.


But let's start in order. His path as an entrepreneur began in the distant 1990s, and the experience he has passed since then in the field of medical technology and pharmaceuticals makes it possible to judge the contribution to the development of this industry and the future of the bio-technology business, which he is engaged in today in Russia and abroad (USA, South Korea , Spain, Central Asia).


In the spirit of the late 80s, it was to commercialize everything around, and the emergence of the market for technological and later medical products in the post-Soviet space helped to combine the love of technical innovation. Becoming an entrepreneur, Shpurov worked in the M&A market in the 90s, providing management services for crisis enterprises, where he achieved some success and which he used as a source of capital for the future. Active operations on the market allowed him to acquire about 500 thousand square meters of real estate both in Moscow and in other cities of Russia, as well as a number of properties in Europe. This was the start for their own business. It was these resources that he began to invest in industrial enterprises in Russia, buying up hopelessly bankrupt industries and making them highly profitable in the future.



Thus, in 2003 the company OJSC "Slavich" was acquired www.slavich.ru in the city of Pereslavl, 4 hours from Moscow. The company was bought in a slump with a debt of about $ 30 million. It now has 7 factories producing photographic paper, photographic plates, microelectronic materials and a growing share of domestic production of flexible packaging materials with multicolor printing. In 2004, at the same place, near the factory base, the Pereslavsky GC Technopark was created, now it is the largest private institute of this kind in Russia in terms of area and number of residents (more than 200), which includes 4 km2 and 560 thousand meters of buildings.


Since 2009, efforts have been made to develop projects in the field of biotechnology "Slavich" has received an unprecedented patent for Russia for the cultivation of new organs inside a person - smooth muscle sphincters. More than 50 therapeutic interventions have been performed with good results of their transplantation into the body of a person who has worn out his own sphincters and needs to be replaced with a threat to life if there is none. Unfortunately, the change in the procedure for registering medical technologies made this project difficult to implement, and the concept of introducing such technologies was rethought.


Now all the efforts and significant investments of the company are directed to the B2B market in the production of medical substances. Their goal is to enter the world biotechnology market within the framework of projects that are being implemented in Pereslavl, Moscow and Kumertau, as well as at a technical site in the Moscow region (Dubna). In addition, one of the goals is to create the production of substances for pharmacology using biotechnological methods - working with colloidal chemistry technologies, the Slavich company implements meson spectroscopy technologies, designs a site for the production of watered films for these purposes and builds workshops for the production of sprays, production of anticancer substances, and also develops partnerships with the Bashkir Medical University and its research base, the Kulakov Research Institute, the IBC Research Institute and in various scientific research.


At the same time, in 2008, Shpurov, together with partners, invested in a large pharmaceutical plant OJSC Krasfarma http://kraspharma.ru in Krasnoyarsk, which at that time was also in a state of industrial default. Timely and correctly directed investments, energetic actions and a good team of its managers could achieve a result in which the plant moved from 63rd to 25th place among Russian manufacturers. New production lines for the production of drugs have been created, new lines of drugs are being developed, which are supplied to pharmacies of ordinary consumers every day. But, most importantly, Kraspharma is actively involved in research and development in the field of pharmacology.


Investment success does not depend on how much an investor knows, but on how realistic he or she is about the limits of his knowledge.

Warren Buffett


From 2010 to 2020, more than $ 70 million was spent on the reconstruction of the pharmaceutical group's enterprises. In 2015, he takes the next big step: acquiring Bebig LLC http://bebig.ru from RUSNANO and a group of private investors . The company has developed a number of innovative products that it produces at its industrial plant in Dubna (Moscow region) in the field of nuclear medicine, which Shpurov is a supporter of - generators, radio preparations and radio sources.



The company increased its capitalization 8 times from 10 million in 2015 to 80 in 2020... The main goal of the company's work, since its foundation in 2004, has been and remains the introduction of innovative methods of treating cancer diseases on the Russian and international markets. On the basis of "Bebig" Shpurov began to conduct his own scientific laboratory developments for the study and treatment of oncology. Today this company is the leader of the brachytherapy market in Russia, specifically, a high-tech method of treating prostate cancer. "Babyig" developed it the third in the world and the first in Russia. This technology is now installed in 28 medical institutions in Russia. The introduction of such innovative methods of treatment can significantly reduce mortality from cancer, apply more gentle methods of treating neoplasms to patients, which has already been proven in a number of patient treatments and scientific experiments.



The next priority task of the company is the development of the developed technology of microspheres for the treatment of liver cancer and a number of related oncological diseases http://www.koreaherald.com/view.php?ud=20200327000656 . An important area of ??business development for Shpurov is the development of partnerships with leading industry technology and scientific leaders. In his case, these are national research universities, including regional and production-related ones, the RUSNANO corporation and its subsidiaries, the leading company in the field of nuclear medicine Eckert & Ziegler https://radiopharma.com/ez-medical/ .



Investment success requires a smart plan and adherence to it. And the last one is the most difficult. Warren Buffett



Using the correctly chosen strategy of Shpurov's company from the beginning of 2020, that is, already during the crisis of the Coronovirus epidemic, they were able to reduce investments in real estate by 50 thousand meters, this made it possible to reduce the amount of consolidated debt to insignificant values, and provided desalinated liquidity reserves, which opened up opportunities for investing in dynamic sectors. As a result of such strategically correct decisions, the American company RAFARMA Pharmaceuticals, Inc http://rafarma.si was acquired , in which it was decided to invest all advanced research programs and thus focus it on the frontier of modern biomedical technologies https: // finance .yahoo.com / news / rafarma-adds-prestigious-board-chairman-133200529.html .



Consolidation of companies from Spain, Hong Kong, Russia and Uzbekistan into this holding, while simultaneously transferring technologies developed in his group, should create a powerful overpass for the development of promising innovations. It will be, firstly, about the technologies of nuclear medicine and theranostics, and secondly about the most advanced technologies for growing organs and tissues, which began at the end of the 10th years of this century, technologies for growing new organs directly in the patient's body were created, partly of which has been patented. Thirdly, this is the production of a number of drugs based on living organisms and bacteria, which are also needed as antiviral drugs against current and future epidemics.



In addition to the production of generics and innovative anti-cancer devices and drugs, the current pharmaceutical holding of Ilya Shpurov is already engaged in the following types of technological medical production: ultrapure materials for electronics, the nuclear industry and isotopes; nuclear emulsion for nuclear physics and muon radiography; membranes for hemosorption and purification of fluids, including blood and plasma; devices for plasma sampling and blood plasmapheresis.



The entrepreneur's related business interests represent the leading directions in the development of the medical business in Russia. For example, the use of the Internet of Things in medicine. The collection and processing of big data provides completely new opportunities for organizing the treatment of people today, evidence-based prediction of the results and budget of treatment, including individual choice of drugs and the successful treatment of the most serious disease in the world - cancer. All together this is a chance for completely new methods of promoting Shpurov's products. It is these views on the nature of the human community and sociality that give the chances of adapting business to the constantly changing landscape of economics and health care, which go hand in hand.



https://www.business-key.com/object/175734/

 

[Bozzie]

PRED's posted on Youtube recently..Not sure how you'd monetize whatever it is these two are doing but at least they have the left fight to produce content.
No way or point in trading this @ 9 cents..It'll be a quite the trick if this ever shows a pulse again.

 

[TheFalls]

were a lot of pumpers were in on it?


<blockquote class="twitter-tweet"><p lang="en" dir="ltr">He was DAMSCONSULTING & pump & dumped <a href="https://twitter.com/search?q=%24PRED&src=ctag&ref_src=twsrc%5Etfw">$PRED</a> from 6 to pennies. Does this sound familiar on how he posts? Don't get suckered by this fraud. Once Gary makes all his money on <a href="https://twitter.com/search?q=%24FNGR&src=ctag&ref_src=twsrc%5Etfw">$FNGR</a> he will change his Twitter handle again and redo it to new investors. <a href="https://t.co/P7rByNVU6a">https://t.co/P7rByNVU6a</a></p>— JBrooks (@ImJamesBrooks) <a href="https://twitter.com/ImJamesBrooks/status/1345481905559527426?ref_src=twsrc%5Etfw">January 2, 2021</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>


https://twitter.com/ImJamesBrooks/status/1345481905559527426

 

[brucefan]

S.A ADVISORY

PRED .08

PRED was our pick for 2020 & it turned out to be a major loser! Most would have moved on to greener pastures. Our greener pastures will house PRED for our stock pick of the year for 2021..Many things went wrong and of course COVID changed everything. The delay in release of their Endometriosis & Infertility test & slow down of stem cells sales resulted from massive clinic closures. The shares currently trade on the "grey's" because of SEC paranoia. The listing is currently being addressed and they will get off on their own or merge into another entity.

The company remains fully reporting/compliant and their auditor is the #1 firm in the USA (Deloitte & Touche)

Their BOD remains solid and surely resembles Fortune 100 management. PRED still has a collaborative relationship with Thermal Fisher (TMO) and a developmental collaborative relationship with Atrin (cancer therapy).

At present, PRED has been ramping-up their COVID 19 saliva testing (6 days/wk) & stem cells sales continues to recover. Most of PRED's assets are not being valued! The genetic library of 300k DNA samples (serious maternal/neonatal disorder worth at least $300 each of that number & 45k are DNA sequenced worth $1000.00 each or est. of $122 million). PRED is not being valued for Endo and Infertility kits, CLIA lab,patents, management or other corp relationships.

The current market-cap is tiny and does not even attempt to measure the discounted valued and future potential that PRED may offer investors. Looking at current share price is a huge error! We believe investors have the opportunity to 10-30X their initial investment even though some might be averaging down from last years price recommendation. The current listing has truly depressed this cutting edge Biotech women's health Covid test company. Take some time and review the size of the industrial segments that they participate in (Endometriosis($2 billion), Stem cells ($2.75 billion),Cancer research( specific to Atrin $4.7 billion),Infertility($2.4 billion), Covid 19 testing(worldwide $20 billion).

Some will think thar the editor has lost his mind by continuing to "howl at the moon" when it comes to PRED! At present PRED has a market-cap of only$18 million. At one point the company sported a market -cap of around $2.5 billion. There has not been that much change since 1 1/2 years ago. We surely did not think it was worth $7.00 and took profit, but @ .07 one must crazy not to reload . We have published since 1984 and of course this is not our first rodeo and believe PRED will be a winner for the patient. Please go and review their complete website http://www.predtechgroup.com .

We rate PRED with our strongest buy recommendation and truly believe that our stock pick for 2021 will take the #1 spot within the 1 year time period.

 

[brucefan]

15 cents print on PRED yesterday, hearing lots of stories. Stay tuned, we will recover our capital over time

In the meantime I hope you have been accumulating RAFA

Its a sleeping giant

( hopefully this link works for everyone)

https://drive.google.com/file/d/1rh0mfeCsX6Cdd1bobc1GBj3LV6H1BliZ/view

 

[brucefan]

15 cents print on PRED yesterday, hearing lots of stories. Stay tuned, we will recover our capital over time

In the meantime I hope you have been accumulating RAFA

Its a sleeping giant

( hopefully this link works for everyone)

https://drive.google.com/file/d/1rh0mfeCsX6Cdd1bobc1GBj3LV6H1BliZ/view

Predictive Biotech: Wound Healing Assay


Predictive Biotech: Wound Healing Assay - YouTube

 

[RapStar]

15 cents print on PRED yesterday, hearing lots of stories. Stay tuned, we will recover our capital over time

In the meantime I hope you have been accumulating RAFA

Its a sleeping giant

( hopefully this link works for everyone)

https://drive.google.com/file/d/1rh0mfeCsX6Cdd1bobc1GBj3LV6H1BliZ/view

I averaged down to incredible levels when it hit 7 pennies. Here's to PRED exploding.

 

[brucefan]

RAFA. https://backend.otcmarkets.com/otcapi/company/financial-report/269085/content

 

[brucefan]

RAFA. https://backend.otcmarkets.com/otcapi/company/financial-report/269085/content

#Rafarma Pharmaceuticals Reports 3rd Quarter Resultshttps://tinyurl.com/y3c6wf3t$RAFA Q3 Highlights> $48.9 Million in Sales > $10.6 Million in Profits> Earned 11.4 Cents EPS on 93.1m S/O > $5.4 Million in Cash> Exported to over 60 Countries Worldwide

 

[brucefan]

[h=1]Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan[/h][h=2][/h][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT]Email [FONT=&quot][/FONT]Print Friendly [FONT=&quot][/FONT]Share
January 29, 2021 10:30 ET | Source: RAFARMA PHARMACEUTICALS INC


Nicosia, Cyprus, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTCRAFA) is pleased to announce its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan which is essentially the Health Department of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000.

Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment.
The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029

 

[thebiggbird]

Is ERI gone?

 

[mickj]

Is ERI gone?

Merged with Caesars.

 

[daytradez]

@BruceFan - been following the SAS Advisory and was lucky enough to get into this at .06. The low! What's the catalyst behind today's surge? I can't find any news.

[COLOR=rgba(0, 0, 0, 0.62)]Market Summary > [COLOR=#202124 !important]Predictive Technology Group Inc[/COLOR]

[/COLOR]
[FONT=&quot]0.67[COLOR=rgba(0, 0, 0, 0.62)] USD+0.57 (570.00%)[/FONT][/COLOR]

 

[daytradez]

Sorry if that didn't transpose properly. Looks like it went to .67 before coming back to .10. Something is going on.

 

[mickj]

It went to .67 for one minute and that was it. Strange.